RENNI®-TAL (Rennie®-Tal)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceHydrotalciteHydrotalcite
Similar drugsTo uncover
  • RENNI®-TAL
    pills inwards 
    Bayer Konsyumer Kare AG     Switzerland
  • Rutatsid®
    pills inwards 
    KRKA, dd, Novo mesto, AO    
    • Dosage form: & nbspchewing tablets
    Composition:

    1 tablet contains:

    active substance: hydrotalcite 500 mg;

    Excipients: Mannitol, corn starch, magnesium stearate, sodium saccharinate, mint flavor, banana flavor.

    Description:

    Round, flat, beveled to the edge tablets of white color with a weak smell of mint, with an imprint in the form of a brand name ("Bayer's" cross).

    Pharmacotherapeutic group:antacid agent
    ATX: & nbsp

    A.02.A.D.04   Hydrotalcite

    Pharmacodynamics:

    Hydrotalcite is an antacid drug. It has a crystalline stratified-mesh structure with a low content of aluminum and magnesium. 1 g of hydrotalcite has a minimum buffer capacity of 26 meq. The drug provides rapid and long-lasting neutralization of hydrochloric acid of gastric juice with maintenance of pH at the optimal therapeutic level between 3 and 5; has a gastroprotective effect due to prolonged binding of pepsin, hydrochloric acid, bile acids; It also activates its own gastric protection factors.

    Pharmacokinetics:

    Due to the RNNI-TAL layered network structure, the release of aluminum and magnesium ions occurs in the stomach gradually depending on the pH value.When used in therapeutic doses RENNI®-TAL is practically not absorbed from the gastrointestinal tract. At the same time, the level of aluminum and magnesium in the blood plasma remains within the physiological norm.

    Indications:

    - Acute and chronic gastritis;

    - Stomach ulcer and duodenal ulcer;

    - reflux esophagitis;

    - heartburn and other symptoms from the gastrointestinal tract, caused by high acidity of the gastric juice.

    Contraindications:

    Individual intolerance, children under 12 years.

    Pregnancy and lactation:

    Although it has been proven that after taking RENNY-TAL, the level of aluminum and magnesium in the blood plasma remains within the physiological norm, during pregnancy the drug should be taken only after consultation with the doctor.

    Taking the drug during lactation does not have a negative effect on the baby.

    Dosing and Administration:

    Take inside. Tablets should be chewed and, if desired, washed with water.

    Adults and children over 12 years of age:

    Acute and chronic gastritis, reflux esophagitis: 500-1000 mg (1-2 tablets) 1-2 hours after meals and before bedtime, and also if necessary.

    Stomach ulcer and duodenal ulcer: 1000 mg (2 tablets) 3-4 times a day after meals and at bedtime. Treatment should continue for 4 weeks after the symptoms completely disappear.

    Heartburn and other gastrointestinal symptoms associated with increased acidity of gastric contents: on 500-1000 mg (1-2 tablets) if necessary.

    The maximum daily dose of hydrotalcite should not exceed 6000 mg (12 tablets).
    Side effects:

    When using the drug in high doses, loosening of the stool is possible.

    Overdose:

    At present, no cases of RENNY®-TAL overdose have been reported.

    Interaction:

    Medications should be taken 1-2 hours before or after taking RENNI®-TAL.

    With the simultaneous use of RENNI-TAL reduces the absorption of antibiotics tetracycline series, fluoroquinolones (ciprofloxacin, ofloxacin) and glycosides.

    Special instructions:

    Patients with impaired renal function, hypophosphatemia, a diet with a low phosphate content should not take RENNI ® -TAL in high doses; long-term use of the drug is also not recommended.

    Effect on the ability to drive transp. cf. and fur:

    Does not affect.

    Form release / dosage:

    Tablets are chewable, 500 mg.

    Packaging:

    For 10 tablets in a blister of "aluminum / PVC" or "aluminum / aluminum", 2 or 5 blisters together with instructions for use in a pack of cardboard.

    Storage conditions:

    Store at a temperature of no higher than 25 ° C, in a dry place protected from light and out of the reach of children.

    Shelf life:

    5 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:П N013508 / 01
    Date of registration:02.04.2008
    The owner of the registration certificate:Bayer Konsyumer Kare AGBayer Konsyumer Kare AG Switzerland
    Manufacturer: & nbsp
    Representation: & nbspBayer HellsCare AG Bayer HellsCare AG Germany
    Information update date: & nbsp17.01.2016
    Illustrated instructions
      Instructions
      Up